Gilead picks former Roche executive to run cell therapy unit Kite

Cindy Perettie, the former Foundation Medicine CEO who most recently ran Roche’s molecular lab division, will follow Christi Shaw in the role. 

By Ned Pagliarulo • May 17, 2023

FTC sues to block Amgen’s $27.8B deal for Horizon

The regulator’s challenge will test a more expansive view of how pharmaceutical mergers could harm consumers. Amgen remains confident it can complete the deal, however.

By Jonathan Gardner • May 16, 2023

Explore the Trendline➔

Top 5 stories from BioPharma Dive

Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.

By BioPharma Dive staff

Sanofi, AstraZeneca study results add support for their RSV drug in infants

The antibody reduced RSV infections requiring hospitalization by 83% in a large study, bolstering evidence for the drug ahead of a U.S. approval decision later this year.

By Christopher Newman • May 12, 2023

Roche pays China-based biotech $70M for a new HER2 drug

The drug, currently in Phase 1, is an oral medicine designed to cross the blood-brain barrier and better treat HER2 tumors that have spread to the brain.

By Jonathan Gardner • May 9, 2023

Novavax cuts workforce by 25% as COVID vaccine sales fall

The layoffs, which will affect hundreds of employees, are part of a major restructuring designed to reduce operational and research spending by as much as half.

By Delilah Alvarado • May 9, 2023

Catalent cuts outlook, delays results as it reveals new hurdles

The pharmaceutical CDMO said it found “significant” issues with its forecasts over the past year, compounding manufacturing problems at three of its plants.

By Ned Pagliarulo • May 8, 2023

Pharma’s commercial model of tomorrow starts today

Today’s commercial model cannot support pharma’s future. A new future calls for bold transformation.

May 8, 2023

Print can help you cut through misinformation

Providing accurate information to protect patients from misinformation is a key goal for pharmaceutical companies, and print media can be a crucial part of the solution.

May 8, 2023

Novo reveals another setback in obesity drug’s launch

U.S. supply of Novo’s Wegovy will be “reduced temporarily,” while the Danish drugmaker gets a new contract manufacturer up and running, executives said.

By Jonathan Gardner • May 4, 2023

Valneva, Pfizer push back timeline for Lyme disease vaccine

After issues with a contract research group, the partners now expect to file an approval application for their shot in 2026, one year later than initially anticipated.

By Delilah Alvarado • May 4, 2023

J&J spinoff Kenvue raises $3.8 billion in year’s largest IPO

Separating out the consumer health division will leave J&J as a slimmed-down company focused on prescription drugs and medical devices.

By Kristin Jensen • May 4, 2023

Lilly’s fortunes rise on back-to-back success for Alzheimer’s, obesity drugs

At more than $400 billion, Lilly’s market value is nearing J&J’s despite the company earning less than one-third as much revenue. Strong data for medicines donanemab and Mounjaro are why. 

By Jonathan Gardner • May 4, 2023

FDA approves first RSV vaccine, clearing GSK’s Arexvy for older adults

The decision represents the first fruits of a scientific breakthrough a decade ago that gave drugmakers, among them GSK, Pfizer and Moderna, a blueprint for an effective shot against the virus.

By Delilah Alvarado • Updated May 3, 2023

Lilly drug slows Alzheimer’s decline in large study

The company plans to quickly submit an application for U.S. approval based on the trial results, which showed a consistent benefit to treatment with the drug, called donanemab.

By Jonathan Gardner , Ned Pagliarulo • Updated May 3, 2023

Pfizer turns focus to new drugs as COVID vaccine revenue falls

The drugmaker beat Wall Street’s first quarter forecasts despite a sales drop that puts pressure on it to succeed with upcoming market launches.

By Jonathan Gardner • May 2, 2023

FDA clears Pfizer’s pneumococcal vaccine for infants and children

Pfizer’s latest Prevnar shot covers 20 strains of the virus, more than the 13 covered by its previous version and the 15 by Merck’s Vaxneuvance.

By Delilah Alvarado • Updated May 3, 2023

AbbVie weathers first months of biosimilar challenge to top-selling Humira

While Humira sales declined, the drop was mostly due to price concessions AbbVie made to secure equal insurer access in the face of copycat competition.

By Ned Pagliarulo • April 28, 2023

Lilly plans dash to market for weight loss drug after trial win

The drugmaker will use a priority review voucher in a bid to secure FDA approval of Mounjaro in obesity by late this year or early next.

By Jonathan Gardner • April 27, 2023

Lilly drug Mounjaro succeeds in second weight loss study

Trial participants nearly 16% of their body weight in a finding that should help the closely watched GLP-1 drug gain an FDA approval for obesity.

By Jonathan Gardner • April 27, 2023

Bristol Myers’ Caforio stepping down as CEO in November

Commercial chief Christopher Boerner will take over after spending the next six months as chief operating officer. Giovanni Caforio will continue to serve as chair of Bristol Myers’ board.

By Jonathan Gardner • Updated April 26, 2023

Roche’s new eye drug pressures Eylea with strong launch

One year after its market debut, the company’s AMD drug Vabysmo is on track for blockbuster sales as Regeneron’s rival treatment faces new threats.

By Jonathan Gardner • April 26, 2023

Bristol Myers boosts cell therapy production with Novartis plant

Accessing the Illinois facility will expand Bristol Myers’ supply of viral vectors following manufacturing struggles with CAR-T drugs Abecma and Breyanzi.

By Kristin Jensen • April 26, 2023

Novartis trims 10% of drug pipeline in research cutback

The company cut about 20 early-stage projects, including nine solid tumor programs, after reviewing their strategic fit and commercial potential.

By Christopher Newman • April 25, 2023

J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market

The planned IPO by the pharma’s consumer arm would value the new standalone company at over $40 billion.

By Ned Pagliarulo • April 25, 2023

Lilly sells emergency diabetes drug for $500M

The divestment of Baqsimi to Amphastar could net Lilly more than $1 billion if sales goals are met.

By Jonathan Gardner • April 24, 2023